Greg Osborne

Greg Osborne is a Principal Scientist at Sosei Heptares. Since joining in 2010 Greg has been responsible for leading drug discovery programs within CNS, GI and inflammation disease areas. Greg manages Sosei Heptares invitro Screening, Assay Development and Compound Management teams within Discovery Molecular Pharmacology and has an extensive background in GPCR pharmacology and hit to candidate identification.
Prior to Sosei Heptares, Greg spent 6 years at GlaxoSmithKline as an invitro screening scientist working in High Throughput Screening and Compound profiling on GPCRs within the cellular screening group.